O	0	3	Can
B-intervention	4	15	polyacrylic
I-intervention	16	20	acid
O	21	26	treat
O	27	33	sexual
O	34	45	dysfunction
O	46	48	in
O	49	54	women
O	55	59	with
O	60	66	breast
O	67	73	cancer
O	74	83	receiving
O	84	93	tamoxifen
O	93	94	?

O	95	100	There
O	101	103	is
O	104	105	a
O	106	110	lack
O	111	113	of
O	114	120	safety
O	121	125	data
O	126	136	supporting
O	137	140	the
O	141	144	use
O	145	147	of
O	148	155	hormone
O	156	163	therapy
O	164	166	in
O	167	172	women
O	173	176	who
O	177	181	have
O	182	185	had
O	186	192	breast
O	193	199	cancer
O	200	203	and
O	204	207	who
O	208	212	have
O	213	223	complained
O	224	226	of
O	227	240	genitourinary
O	241	249	syndrome
O	250	252	of
O	253	262	menopause
O	263	264	(
O	264	267	GSM
O	267	268	)
O	268	269	.

O	270	273	The
O	274	283	objective
O	284	287	was
O	288	290	to
O	291	295	test
O	296	299	the
O	300	308	efficacy
O	309	311	of
O	312	315	two
O	316	319	non
O	319	320	-
O	320	328	hormonal
O	329	338	therapies
O	339	342	for
O	343	350	vaginal
O	351	358	dryness
O	358	359	.

O	360	364	This
O	365	368	was
O	369	370	a
O	371	381	randomized
O	382	387	trial
O	388	392	with
B-total-participants	393	395	52
B-eligibility	396	401	women
I-eligibility	402	406	with
I-eligibility	407	413	breast
I-eligibility	414	420	cancer
I-eligibility	421	424	who
I-eligibility	425	429	were
I-eligibility	430	435	being
I-eligibility	436	443	treated
I-eligibility	444	448	with
I-eligibility	449	458	tamoxifen
I-eligibility	459	462	and
I-eligibility	463	466	who
I-eligibility	467	477	complained
I-eligibility	478	480	of
I-eligibility	481	488	vaginal
I-eligibility	489	496	dryness
O	496	497	.

O	498	501	The
O	502	512	volunteers
O	513	521	answered
O	522	525	two
O	526	540	questionnaires
O	541	543	to
O	544	552	evaluate
O	553	559	sexual
O	560	568	function
O	569	570	(
O	570	576	Female
O	577	583	Sexual
O	584	592	Function
O	593	598	Index
O	598	599	,
O	600	604	FSFI
O	604	605	)
O	606	609	and
O	610	611	a
O	612	622	customized
O	623	626	GSM
O	627	640	questionnaire
O	640	641	.

O	642	645	The
O	646	651	women
O	652	656	were
O	657	667	randomized
O	668	672	into
O	673	676	two
O	677	683	groups
O	683	684	:
B-intervention-participants	685	687	25
O	688	689	(
O	689	691	48
O	691	692	.
O	692	693	1
O	693	694	%
O	694	695	)
O	696	698	in
O	699	702	the
O	703	714	polyacrylic
O	715	719	acid
O	720	725	group
O	726	729	and
B-control-participants	730	732	27
O	733	734	(
O	734	736	51
O	736	737	.
O	737	738	9
O	738	739	%
O	739	740	)
O	741	743	in
O	744	747	the
B-control	748	757	lubricant
I-control	758	763	group
O	763	764	,
O	765	770	using
O	771	777	either
O	778	781	one
O	782	784	of
O	785	788	the
O	789	799	treatments
O	800	803	for
O	804	806	30
O	807	811	days
O	811	812	,
O	813	816	and
O	817	822	after
O	823	827	they
O	828	832	were
O	833	840	invited
O	841	843	to
O	844	850	answer
O	851	854	the
O	855	869	questionnaires
O	870	875	again
O	875	876	.

O	877	882	There
O	883	886	was
O	887	898	improvement
O	899	901	in
O	902	905	the
B-outcome	906	910	FSFI
O	911	916	after
O	917	921	both
O	922	932	treatments
O	932	933	.

O	934	937	The
O	938	949	polyacrylic
O	950	954	acid
O	955	960	group
O	961	967	showed
O	968	969	a
B-outcome	970	978	decrease
I-outcome	979	981	in
I-outcome	982	988	sexual
I-outcome	989	1000	dysfunction
O	1001	1005	from
O	1006	1008	96
O	1008	1009	%
O	1010	1012	to
O	1013	1015	24
O	1015	1016	%
O	1017	1018	(
O	1018	1019	p
O	1020	1021	<
O	1022	1023	0
O	1023	1024	.
O	1024	1028	0001
O	1028	1029	)
O	1030	1033	and
O	1034	1037	the
O	1038	1047	lubricant
O	1048	1053	group
O	1054	1060	showed
O	1061	1062	a
O	1063	1071	decrease
O	1072	1076	from
O	1077	1079	88
O	1079	1080	.
O	1080	1081	9
O	1081	1082	%
O	1083	1085	to
O	1086	1088	55
O	1088	1089	.
O	1089	1090	6
O	1090	1091	%
O	1092	1093	(
O	1093	1094	p
O	1095	1096	=
O	1097	1098	0
O	1098	1099	.
O	1099	1103	0027
O	1103	1104	)
O	1104	1105	.

O	1106	1109	The
O	1110	1117	results
O	1118	1120	of
O	1121	1125	this
O	1126	1131	study
O	1132	1138	showed
O	1139	1143	that
O	1144	1148	both
O	1149	1159	treatments
O	1160	1168	improved
O	1169	1175	sexual
O	1176	1184	function
O	1184	1185	;
O	1186	1193	however
O	1193	1194	,
O	1195	1206	polyacrylic
O	1207	1211	acid
O	1212	1215	was
O	1216	1224	superior
O	1225	1227	to
O	1228	1231	the
O	1232	1241	lubricant
O	1242	1244	in
O	1245	1253	treating
O	1254	1260	sexual
O	1261	1272	dysfunction
O	1272	1273	.
